A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | MicrobiomeTrials← Back to trialsNCT06095128
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2024-06-12Est. Completion: 2027-07-09
Enrollment target: 60 participants Locations- Digestive Health Specialsits, Dothan, Alabama, United States
- GI Alliance Sun City, Sun City, Arizona, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Hoag Hospital Newport Beach, Newport Beach, California, United States
- Endoscopic Research Inc, Orlando, Florida, United States
- Alliance Clinical Research of Tampa, LLC, Tampa, Florida, United States
- Gastroenterology Consultants, P.C., Roswell, Georgia, United States
- University of Chicago Medicine, Chicago, Illinois, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- University of Louisville, Louisville, Kentucky, United States
- GI Alliance, Metairie, Louisiana, United States
- Tulane University, New Orleans, Louisiana, United States
- Capital Digestive Care - MGG Group - Chevy Chase Clinical Research, Chevy Chase, Maryland, United States
- Huron Gastroenterology Associates, P.C., Ypsilanti, Michigan, United States
- MNGI Digestive Health, PA, Plymouth, Minnesota, United States
- Mid-America Gastro-Intestinal Consultants, Kansas City, Missouri, United States
Other microbiome trials you might be interested in
Inflammatory Bowel Diseases (IBD)Crohn DiseaseColitis, Ulcerative
Difficult-to-treat inflammatory bowel disease (DTT-IBD) represents a heterogeneous group of patients with treatment-refr…
Multiple LocationsEst. completion Oct 31, 2032
Inflammatory Bowel Disease
This study evaluates oral Lactobacillus reuteri as an adjunct therapy for 2 months. Endoscopic assessments will be perfo…
Suqian, ChinaCompleted Mar 30, 2026
BVL Clinical Research, Liberty, Missouri, United StatesWashington University School of Medicine, St Louis, Missouri, United StatesNYU Langone Health, New York, New York, United StatesWeill Cornell Medical College- New York Presbyterian Hospital, New York, New York, United StatesDigestive Health Partners, Asheville, North Carolina, United StatesUniversity of North Carolina, Chapel Hill, North Carolina, United StatesUniversity of Cincinnati, Cincinnati, Ohio, United StatesOhio Gastroenterology group, Inc., Columbus, Ohio, United StatesGastro Intestinal Research Institute of Northern Ohio, LLC., Westlake, Ohio, United StatesAllegheny Health Network, Wexford, Pennsylvania, United StatesUniversity Gastroenterology, Providence, Rhode Island, United StatesSanford Health Research, Rapid City, South Dakota, United StatesThe University of Texas Health Science Center at Houston, Houston, Texas, United StatesGI Alliance - Mansfield, Mansfield, Texas, United StatesGastroenterology Research of San Antonio, LLC, San Antonio, Texas, United StatesTexas Digestive Disease Consultants (TDDC), Southlake, Southlake, Texas, United StatesTyler Research Institute, LLC, Tyler, Texas, United StatesGI Alliance - Webster, Webster, Texas, United StatesUniversity of Utah Health, Salt Lake City, Utah, United StatesWashington Gastroenterology- GIA, Tacoma, Washington, United StatesBarrie GI Associates Inc., Barrie, Ontario, CanadaLondon Health Sciences Centre, London, Ontario, CanadaWest GTA Endoscopy Inc., Mississauga, Ontario, CanadaViable Clinical Research - North Bay, North Bay, Ontario, CanadaToronto Immune and Digestive Health Institute Inc. (TIDHI), North York, Ontario, CanadaABP Research Services Corp., Oakville, Ontario, CanadaTaunton Surgical Centre, Oshawa, Ontario, CanadaToronto Digestive Disease Associates (TDDA) Inc., Vaughan, Ontario, CanadaThe Research Institute of the McGill University Health Centre, Montreal, Quebec, CanadaRecruiting
Recurrent C. Difficile (rCDI)Ulcerative Colitis (UC)Metabolic Syndrome (MetS)
The gut microbiota plays a key role in immunity and metabolism and contributes to diseases such as recurrent C. difficil…
Rome, ItalyEst. completion Jan 19, 2029